GEN-003

BIOLOGICAL3 trials

Sponsors

Genocea Biosciences, Inc.

Conditions

Genital HerpesGenital Herpes Simplex Type 2HSV-2 Infection

Phase 1

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

CompletedNCT01667341

Genocea Biosciences, Inc.Genital Herpes Simplex Type 2

Start: 2012-07-31End: 2014-05-09Updated: 2018-06-01

Phase 2

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

CompletedNCT02515175

Genocea Biosciences, Inc.Genital Herpes Simplex Type 2

Start: 2015-11-30End: 2017-05-25Updated: 2018-05-22

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

TerminatedNCT03146403

Genocea Biosciences, Inc.Genital Herpes, HSV-2 Infection

Start: 2017-05-24End: 2018-06-11Updated: 2019-02-19

Related Papers

Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.

2019-05-1525 citations

Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial

The Journal of Infectious Diseases2017-01-3071 citations